Long-term benefit of SABR for operable early-stage NSCLC shown in new study

long term benefit of sabr for operable early stage nsclc shown in new study

Sumary of Long-term benefit of SABR for operable early-stage NSCLC shown in new study:

  • A new study from researchers at The University of Texas MD Anderson Cancer Center showed that stereotactic ablative radiotherapy (SABR) was as effective as surgery at providing long-term benefits to patients with operable early-stage non-small cell lung cancer (NSCLC) and generated minimal side effects.
  • The study is the first of its kind to compare long-term results of SABR against surgical treatment in patients with operable early-stage NSCLC.
  • , professor of Thoracic and Cardiovascular Surgery — were published today in The Lancet Oncology.
  • “After surgical resection, recovery may be prolonged and there can be significant loss of lung function depending on the amount of lung removed,” Chang said.
  • “However, SABR functions as a non-invasive ‘knife’ to eliminate cancer with minimal side effects.
  • Patients are treated in 30 minutes as an outpatient procedure, and they can return home or even work the same day after therapy is delivered.
  • ” The study builds on the pooled analyses of two randomized studies (STARS and ROSEL trials), published in 2015, that investigated the advantages of SABR versus a surgical procedure called video-assisted thoracoscopic surgical lobectomy with mediastinal lymph node dissection (VATS L-MLND).
  • 31, 2017, and compared their results to propensity-matched patients undergoing surgery during the same time period.

Want to know more click here go to source.

From -


Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.